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Abstract
 
The Kit receptor functions in hematopoiesis, lymphocyte development, gastrointestinal tract
motility, melanogenesis, and gametogenesis. To investigate the roles of different Kit signaling
pathways in vivo, we have generated knock-in mice in which docking sites for PI 3-kinase
(Kit
 
Y719
 
) or Src kinase (Kit
 
Y567
 
) have been mutated. Whereas steady-state hematopoiesis is normal
in Kit
 
Y719F/Y719F
 
 and Kit
 
Y567F/Y567F
 
 mice, lymphopoiesis is affected differentially. The Kit
 
Y567F
 
mutation, but not the Kit
 
Y719F
 
 mutation, blocks pro T cell and pro B cell development in an
age-dependent manner. Thus, the Src family kinase, but not the PI 3-kinase docking site in
Kit, mediates a critical signal for lymphocyte development. In agreement with these results,
treatment of normal mice with the Kit tyrosine kinase inhibitor imatinib (Gleevec
 
®
 
) leads to
deficits in pro T and pro B cell development, similar to those seen in Kit
 
Y567F/Y567F
 
 and Kit
 
W/W
 
mice. The two mutations do not affect embryonic gametogenesis but the Kit
 
Y719F
 
 mutation
blocks spermatogenesis at the spermatogonial stages and in contrast the Kit
 
Y567F
 
 mutation does
not affect this process. Therefore, Kit-mediated PI 3-kinase signaling and Src kinase family
signaling is highly specific for different cellular contexts in vivo.
Key words: Kit receptor signaling • Src kinase • PI 3-kinase • pro T and pro B cell development
 
Introduction
 
Kit encodes a growth factor receptor with ligand-dependent
tyrosine kinase activity (1–3). Kit ligand, KitL, is the only
known ligand of the Kit receptor (4). The Kit and KitL
genes are encoded at the White spotting (W) and Steel (Sl)
loci in the mouse, respectively, and loss of function mutations
in the Kit and KitL genes generate deficiencies in several
cell systems during embryonic development and in the
postnatal organism: in hematopoiesis, the pigmentary system,
intestinal pacemaker cells, and in gametogenesis. In hemato-
poiesis, Kit receptor signaling is critical in the stem cell
hierarchy, in erythropoiesis, in mast cell development and
function, and megakaryopoiesis (5–8). In adult lymphopoiesis,
in an age-dependent fashion, Kit has a critical role in pro T
and pro B cell subsets (9). In the gastrointestinal tract, Kit
signaling is required in interstitial cells of Cajal (ICC),
which function as pacemaker cells and mediate inputs from
the enteric nervous system to smooth muscle cells (10–12).
KitL binding to the receptor mediates receptor dimeriza-
tion, activation of kinase activity, and autophosphorylation.
Kit activates several signaling cascades leading to cell prolif-
eration, cell survival and other cellular responses. The signaling
cascades that are activated by Kit signaling include activation
of PI 3-kinase, Src kinases, tyrosine phosphatases, STATs,
RAS, RAC, PLC-
 
 
 
, and CBL. As part of the activation of
some of these cascades, signaling molecules containing SH2
domains bind to tyrosine phosphate residues on the activated
receptor tyrosine kinase. In the Kit receptor, tyrosines 567,
569, and 719 are known docking sites for src kinases, tyrosine
phosphatases, and the p85 subunit of PI 3-kinase, respectively.
In vitro studies showed that Kit tyrosine-567 and 719–
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phenylalanine substitution mutations block docking and
activation of Src family kinase and PI 3-kinase signaling,
respectively (13, 14). Furthermore, the Kit tyrosine-567–
phenylalanine substitution mutation blocks docking of the
tyrosine phosphatase SHP-2 (15), the adaptor protein APS,
and the Csk-homologous kinase (CHK; reference 16).
Studies in BM-derived mast cells (BMMC) have pro-
vided insight about the mechanism by which Kit mediates
various cellular responses including cell proliferation, sur-
vival, adhesion, actin reorganization, membrane ruffling,
and secretion. In BMMC, mutation of the Kit receptor
binding sites for class IA PI 3-kinase adaptor proteins,
KitY719, and for Src, Kit Y567, were shown to affect cell
proliferation, survival, adhesion, and secretion to differing
degrees (13, 14, 17). Whereas Kit-mediated PI 3-kinase ac-
tivation contributes to the mitogenic and survival responses
in BMMC, in the secretory response, cell adhesion re-
sponse, actin polymerization, and membrane ruffling re-
sponses, Kit-mediated PI 3-kinase activation is critical.
Therefore, divergent downstream signaling pathways are
responsible for the generation of various cellular responses.
Diverse Kit receptor functions in vivo may be deter-
mined by unique cell type–specific signaling networks. To
investigate the contribution of different signaling pathways
to various Kit receptor–mediated cellular responses in vivo,
we and others have previously generated mice in which the
PI 3-kinase binding site Kit
 
Y719
 
 was mutated (18, 19). The
Kit
 
Y719F
 
 mutation was found to affect Kit function only in
specific developmental processes, and this is in contrast to
other mutations in the Kit receptor gene, i.e., 
 
W
 
v
 
, which
broadly affect Kit function in hematopoiesis, gametogene-
sis, and melanogenesis. Although the mutation fails to affect
steady-state hematopoiesis and skin mast cells, peritoneal
mast cell numbers are reduced significantly. Furthermore,
although Kit has important functions at multiple stages in
embryonic and postnatal gametogenesis, PI-3 kinase signal-
ing is critical only in a specific subset of the postnatal stages
in the ovary and testis. We now have generated mice in
which the Src binding site in the Kit receptor gene, Kit
 
Y567
 
,
was mutated. Here, we compared the phenotypes of
Kit
 
Y567F/Y567F
 
 with the phenotypes of Kit
 
Y719F/Y719F
 
 mice
that display remarkable differences within hematopoiesis as
well as germ cell development.
 
Materials and Methods
 
Generation of Mutant Kit
 
Y567F
 
 Mice
 
Site-directed mutagenesis was performed on a 2.4-kb SpeI-KpnI
genomic Kit fragment including exons 10–13, mutating tyrosine
567 to phenylalanine in exon 11. The mutant Kit genomic frag-
ment was inserted into a fragment including Kit exons 8–13. A
neomycin-resistance gene expression cassette flanked by loxP sites
was inserted into a SnaBl site in intron 9. For negative selection a
diphtheria toxin A (DT-A) gene cassette, provided by Frank Cos-
tantini (Columbia University, New York, NY), was placed at the
3
 
 
 
 end of the targeting construct. 129/SvJ embryonic stem (ES)
cells (CJ7; Swiatek and Gridley, 1993) were electroporated with
linearized targeting construct following standard protocols. Neo-
 
mycin-resistant ES cell clones were isolated and analyzed for ho-
mologous recombination. First, ES cell clones were screened by a
PCR strategy (primer set A/B) in which a 5.0-kb fragment in-
cluding the neo-cassette and a genomic region outside the target
construct was amplified. Correctly targeted ES cell clones then
were verified by Southern blot analysis and the presence of the
Kit
 
Y567F
 
 was confirmed by sequence analysis. Correctly targeted
ES cell clones were microinjected into C57BL/6J blastocysts and
male mice displaying 85–100% chimerism were backcrossed to
C57BL/6J females for germline transmission.
The floxed neo-cassette was excised in vivo by mating het-
erozygous mutant males with EIIa-cre transgenic females (20).
EIIa-cre transgenic mice on a C57BL/6J background (N10) were
kindly provided by Monica Bessler (Washington University
Medical School, St. Louis, MO). Excision of the neo-cassette was
monitored by using DNA digested with BamHI and Southern
blot analysis using Kit- and Neo-specific probes. In addition the
residual lox site and adjacent multiple cloning sites were identi-
fied by PCR (lox-PCR: primer set C/D). Primer A: 5
 
 
 
-AA-
GAACTCGTCAAGAAGGCGATAGAAGGCG-3
 
 
 
; primer B:
5
 
 
 
-CTCCGTTGAGTGCAGAAGGTTC-3
 
 
 
; primer C: 5
 
 
 
-AC-
GATGTGGGCAAGAGTT-3
 
 
 
; and primer D: 5
 
 
 
-GATACT-
GTTAACATTTCGATACAGATGTTTAGC-3
 
 
 
.
 
Animals
 
 C57Bl/6J mice were purchased from the Jackson Immuno-
Research Laboratories. The Kit
 
Y719F/Y719F
 
 mice were described pre-
viously (18). Kit
 
Y719F/Y719F
 
 and Kit
 
Y567F/Y567F
 
 mice used for experiments
were backcrossed six times (N6) and three times (N3), respectively,
to C57Bl/6J mice. Littermates were used as control. Double mu-
tant Kit
 
Y719F/Y719F
 
 
 
 
 
c
 
 
 
/
 
 
 
 were generated by crossing Kit
 
Y719F/
 
 
 
mice with 
 
 
 
c
 
 
 
/
 
 
 
 mice (21) as described for Kit
 
W/W
 
 
 
 
 
c
 
 
 
/
 
 
 
 (22).
 
Mast Cell Cultures
 
BMMCs from Kit
 
Y567F/Y567F
 
, Kit
 
Y719F/Y719F
 
, and control mice
were derived and cultured as published (14). Kit cell surface ex-
pression was monitored by FACS
 
®
 
 analysis (see Flow Cytometry
Analysis below). Before stimulation, BMMC were washed free of
growth factor and cultured in serum-free medium (Stemspan SF
expansion medium; StemCell Technologies, Inc.) for 6 h.
 
Cell Proliferation and Apoptosis
 
Proliferation assays were performed as described previously
(23). In brief, 10
 
5
 
 starved BMMC were seeded at 0.2 ml/well in
triplicate in 96-well plates, followed by stimulation with KitL
(Peprotech) for 24 h. After 20 h, 0.5 
 
 
 
Ci of [
 
3
 
H]thymidine was
added for 4 h. Cells were harvested and 
 
 
 
-emission determined.
For apoptosis assays, cells were grown in serum-free media sup-
plemented with IL-3 (20 ng/ml) for 12 h, plated at 10
 
6
 
 cells per 2
ml/well in six-well plates, starved for 1 h, and stimulated with
KitL at the indicated concentrations for 50 h. Cells were har-
vested and analyzed by flow cytometry using the Annexin
V–FITC detection Kit I (BD Biosciences).
 
Immunoprecipitation and Western Blotting
 
Starved BMMC were stimulated with KitL (100 ng/ml) or not
for 5 min (Kit IP) or 10 min (Lyn IP and Western blot) at 37
 
 
 
C.
Cells were lysed in NP-40 lysis buffer containing 50 mM Tris-
HCl (pH 8.0), 150 mM NaCl, 5 mM EDTA, 1% NP-40, 2 mM
Na
 
3
 
VO
 
4
 
, 1 mM phenylmethylsulfonyl fluoride, 10 mM NaF, and
20 
 
 
 
l/ml proteinase inhibitor cocktail (Sigma-Aldrich). Cleared
lysates were precipitated overnight using anti-Kit or anti-Lyn an- 
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tibody (Santa Cruz Biotechnology, Inc.) and fractionated by
SDS-PAGE. For Western blotting, anti-Kit (Oncogene Research
Products), anti-Lyn and anti-Actin (Santa Cruz Biotechnology,
Inc.), anti–phospho-c–Kit (Tyr 719; Cell Signaling), and anti–PI
3–kinase p85 (Upstate Biotechnology) were used.
 
Determination of Peripheral Blood Parameters, Mast Cell 
Numbers, and Histological Analysis
 
Peripheral blood parameters were analyzed as described previ-
ously (25). Skin mast cell numbers were determined as described
previously (25). Mast cells per 1-cm skin between the epidermis
and the panniculus were counted in several independent sections
and averaged. Peritoneal mast cells obtained by lavage of the peri-
toneal cavity with 5 ml of PBS were cytospun on slides and
stained with Toluidine blue or Alcian blue/Safranin and counted.
Berberine sulfate staining for heparin detection was performed
according to Enerback (24). 8-
 
 
 
m paraffin sections from Bouin’s
fixed testis were stained with Hematoxylin-Periodic acid-Schiff
according to standard protocol.
 
Flow Cytometry Analysis
 
All the monoclonal antibodies used are from BD Biosciences if
not differently indicated. Appropriately labeled isotype controls
and single/double color–stained cells were always used to define
the specific gates. When required, murine Fc block (anti–mouse
CD16/CD32 monoclonal antibody) was used. A FACScalibur
 
®
 
(BD Biosciences) was used for analysis. 
 
BMMC Analysis.
 
3 
 
 
 
 10
 
5
 
 BMMC resuspended in staining
buffer (PBS without Ca
 
2
 
 
 
 and Mg
 
2
 
 
 
, 3% FCS, 0.02% NaN
 
3
 
) were
stained for Kit with PE-conjugated anti-Kit antibody and for FceRI
by incubation with mouse IgE anti-DNP (clone SPE-7; Sigma-
Aldrich) followed by FITC-conjugated IgE monoclonal antibody.
 
Thymocyte Analysis.
 
Thymi were mechanically dissociated
into a single cell suspension, washed, resuspended in staining
buffer, and counted. The triple negative (TN) subsets were re-
solved by staining 1.5 
 
 
 
 10
 
6
 
 thymocytes with a mix of lineage-
specific monoclonal antibodies (anti–mouse Ter119, B220, Mac-1,
Gr-1, CD4, CD8, and CD3) PE conjugated, anti–mouse CD44
Cy-Chrome conjugated, and anti–mouse CD25 FITC conju-
gated. CD44 and CD25 expression was analyzed on the gated
lineage negative cells. 
 
B Cell Analysis.
 
Bone marrow was flushed from femurs with
PBS, and a single cell suspension was obtained by gentle pipetting
and passage through a nylon strainer (Falcon). 1.5 
 
 
 
 10
 
6
 
 cells re-
suspended in staining buffer were incubated for 10 min at 4
 
 
 
C
with 1 
 
 
 
g of murine Fc block and then labeled with the appropri-
ate monoclonal antibodies mixes: anti–mouse B220 APC/anti-
CD43 Cy-Chrome/anti–mouse IgM FITC, or anti-B220 APC/
anti-CD43 Cy-Chrome/CD24 FITC/BP-1 PE. Anti-Kit PE and
anti-CD19 PE were also used in some experiments. When not
immediately analyzed the labeled cells were fixed by CytoFix (BD
Biosciences) according to the manufacturer’s instruction.
 
Pharmacological Treatments
 
STI571 (Gleevec
 
®
 
, Imatinib; Novartis) was administrated in-
traperitoneally 45 mg/Kg twice daily as shown. At the indicated
times animals were killed and thymi and bone marrow were har-
vested for FACS
 
®
 
 analysis.
 
Statistics
 
The Student’s 
 
t
 
 test assuming unequal variances between the two
samples was used to determine the significance of differences of
 
lymphocyte subsets between mutants and their littermates.
Groups were judged to differ significantly at P 
 
 
 
 0.05.
 
Online Supplemental Material
 
Fig. S1 shows the pigmentation phenotypes of 
 
 
 
/
 
 
 
, Kit
 
Y567F/Y567F
 
,
Kit
 
Y719F
 
/
 
Y719F
 
, Kit
 
W
 
/
 
 
 
, Kit
 
Y567F
 
/
 
W
 
, and Kit
 
Y719F
 
/
 
W
 
 mice. Fig.
S1 is available at http://www.jem.org/cgi/content/full/jem.
20031983/DC1.
 
Results 
 
Point Mutation in the Kit Receptor Gene, Kit
 
Y567F
 
, Obtained
by Gene Targeting Abolishes Lyn Signaling In Vivo.
 
To gain
insight into the mechanism of Kit-mediated Src family ki-
nase signaling in vivo, we replaced Kit tyrosine 567 with
phenylalanine in the murine Kit gene by using knock-in
gene-targeting technology. A targeting construct was made
that contained the tyrosine–phenylalanine substitution mu-
tation in Kit exon 11 and a neomycine resistance (neo) cas-
sette flanked by loxP sites for subsequent removal in vivo
(Fig. 1 A). Homologous replacement in ES cells produced
three correctly targeted ES cell clones identified by PCR,
Southern blot, and sequencing analysis. These ES cell
clones were microinjected into C57BL/6J blastocysts, chi-
meras were produced, which gave rise to germline trans-
mission. We have noticed previously that inclusion of a
neo-cassette in intronic Kit sequences can interfere with
the expression of the Kit gene (18). Therefore, we re-
moved the neo-cassette by cre-mediated excision in vivo as
described previously (18). Both heterozygous and homozy-
gous mutant male and female Kit
 
Y567F/
 
 
 
 and Kit
 
Y567F/Y567F
mice were fertile.
To establish that Kit-mediated Src kinase signaling is
abolished in KitY567F/Y567F mice we prepared BMMC
from these animals. Mutant BMMC obtained from the
KitY567F/Y567F mice have comparable characteristics com-
pared with wild-type BMMC, i.e., expression of cell surface
markers, except that Kit receptor levels were reduced to
 50–60% of normal levels (Fig. 1 B). In addition, Kit re-
ceptor levels are reduced also in other Kit-expressing cell
types such as lineage-negative BM cells (unpublished data).
To investigate whether Kit expression was reduced at the
RNA or protein level, we perfomed RNase protection as-
says with RNA from Kit /  and KitY567F/Y567F BMMC to
determine Kit RNA levels and found that Kit transcripts are
reduced to 50–60% of normal levels (unpublished data). We
therefore presume that the remaining lox site and flanking
sequences in Kit intron 9 of the mutant affect Kit RNA
transcription and/or splicing. It is also possible that the
KitY567F mutation affects Kit receptor metabolism/turnover
leading to reduced Kit receptor levels. Experiments using
mutant BMMC do not support such an explanation, i.e.,
Kit protein stability upon Kitl stimulation of mutant Kit
parallels that of wild-type Kit (unpublished data). Because
reduced levels of Kit expression may potentially contribute
to the phenotype observed in KitY567F/Y567F mice (see be-
low), it is important to note that lymphocyte development
is normal in heterozygous KitW/  mice (9).Kit Signaling in Pro T and Pro B Cells 870
To establish that Kit-mediated Lyn signaling is abolished
in KitY567F/Y567F BMMC, we determined whether Lyn and
Kit could be coimmunoprecipitated after stimulation of the
mutant BMMC with KitL. Cell extracts were immunopre-
cipitated with anti-Lyn antibody, fractionated by SDS-
PAGE, and immunoblotted with anti-Kit and anti-Lyn an-
tibodies. As expected in extracts from wild-type BMMC
Kit could be detected, in BMMC isolated from KitY567F/Y567F
mice association of Lyn with Kit did not occur (Fig. 1 C).
However, association of the activated Kit receptor with the
p85 subunit of PI 3-kinase was not affected by the KitY567F
mutation. In agreement with this finding Kit tyrosine 719
was phosphorylated comparably in stimulated wild-type
and mutant BMMC (Fig. 1 C).
Steady-state Hematopoiesis and Melanogenesis Are Affected
Minimally in KitY567F/KitY567F and KitY719F/Y719F Mice. In
hematopoiesis KitL and Kit have multiple roles. In mice
carrying W mutations effects are seen in the stem cell com-
partment, erythropoiesis, and in mast cells (7, 8). Interest-
ingly, in both KitY719F/Y719F as well as in KitY567F/Y567F mice
hematocrit values and red blood cell, white blood cell, and
platelet numbers in mutant mice did not deviate from nor-
mal (unpublished data). These results suggest that the Kit-
mediated PI 3-kinase signaling and Src kinase family signal-
ing do not have a major role in steady-state hematopoiesis.
Whereas, no pigmentation phenotype was evident in
KitY719F/Y719F mutant mice, hemizygous mutant KitY719F/W
mice displayed a pigmentation phenotype that was stronger
than the depigmentation seen in KitW/  mice (Fig. S1). In
KitY567F/Y567F mice ventral depigmentation was seen with
variable penetrance and in hemizygous KitY567F/W this phe-
notype was enhanced (Fig. S1). Thus, both the KitY567F and
the KitY719F affect pigmentation, although minimally.
Age-dependent Effect of the KitY567F Mutation on T and B
Lymphopoiesis. During fetal and neonatal life, Kit plays a
redundant role together with the IL-7 receptor/common
cytokine receptor   chain ( c) in T cell development (22),
and no or only a minor role in B cell development (26). Re-
cently, Waskow et al. (9) described an essential, nonredun-
dant role for Kit function in adult lymphopoiesis. A require-
ment for Kit was found in both pro T and pro B cell subsets,
and, interestingly, this requirement was age dependent (9).
To elucidate the molecular mechanism of Kit signaling in
lymphopoiesis we investigated the effect of the KitY719F and
KitY567F mutations on B and T cell lymphopoiesis.
B Cell Development. Peripheral blood in KitY719F/Y719F
and in KitY567F/Y567F mice contained normal numbers of pe-
ripheral B lymphocytes (unpublished data). Spleen cellularity
in adult mice was not affected in Kit /  (1.4   0.52   108)
and KitY567F/Y567F (1.2   0.52   108) mice, but in KitY567F/Y567F
mice the percentage of splenic B cells (B220  cells) was
slightly increased (unpublished data). Stages of B cell devel-
opment in the bone marrow were separated according to
Hardy et al. into fractions B (B220 CD43 CD24 BP-1 ),
C (B220 CD43 CD24 BP-1 ), D (B220 CD43 IgM ),
and E (B220 CD43 IgM ) to F (B220highCD43 IgM ;
reference 27). Cells in stages B to E represent progressively
Figure 1. Targeted substitution of Kit tyrosine 567 by phenylalanine
in the 129/Sv Kit locus. (A) Schematic representation of targeting
strategy: LoxP sites are indicated by rectangles and a red star highlights
exon 11. For negative selection a diphteria A gene-cassette (DT-A) was
placed at the 3  end of the construct. (A and B) Characterization of
BMMC from KitY567F/Y567F mice. (B) Expression of Kit and Fc RI was
analyzed by FACS®. (C, top) Coimmunoprecipitation of Kit with Lyn
in KitY567F/Y567F and WT BMMC treated with KitL. Starved cells were
treated with and without KitL (100 ng/ml) for 10 min at 37 C. Cell
lysates were immunoprecipitated with anti-Lyn antibody, fractionated
by SDS/PAGE, and blotted with anti-Kit antibody and Lyn antibody.
(Middle) Western blot of KitY567F/Y567F and WT BMMC extracts obtained
after stimulation with KitL (10 min), blotted with anti–phospho-Kit
(Tyr 719), anti-Kit, and anti-actin antibodies is shown. Coimmunopre-
cipitation of the p85 subunit of PI 3-kinase with Kit is shown in the
bottom panel. Extracts of KitY567F/Y567F and WT BMMC treated with
KitL (5 min) were immunoprecipitated with anti-Kit antibody, frac-
tionated by SDS-PAGE, and Western blots developed with anti-Kit and
anti-p85 antibodies.Agosti et al. 871
maturing precursor B cells, and F represents recirculating
mature B cells. Previously, an age-dependent block in B cell
development beginning at stage B, and most evident from
stage C onwards was demonstrated in KitW/W mice. This
progenitor loss was associated with a corresponding relative
increase in percentages of recirculating mature B cells (frac-
tion F; reference 9). In KitY567F/Y567F, but not KitY719F/Y719F
mice older than 9 mo, and not in 4-mo-old mice of any ge-
notype, we found a consistent statistically significant reduc-
tion of cells in fractions C (B220 CD43 CD24 BP-1 )
and D (B220 CD43 /IgM ; Fig. 2 A and Table I). Consis-
tent with these results, the frequencies of Kit  and
CD19  (a B cell commitment marker) cells within the
B220 CD43 CD24high population (these include cells in
fractions B and C) were significantly reduced (Fig. 2 B). The
total number of cells in fraction F, mature recirculating B
lymphocytes (B220highCD43 IgM ), were not significantly
reduced in KitY567F/Y567F when compared with wild-type
mice (Fig. 2 A, and Table I). Whereas the block is more
complete in KitW/W mice (9) than in KitY567F/Y567F mice, re-
markably both mutants display an age-dependent block at
the same stage in B cell development.
T Cell Development. First, thymocyte development in
KitY719F/Y719F mice was investigated. Early thymocyte
populations were dissected into CD3 CD4 CD8  (TN
stages 1–4: CD44  CD25  [TN1]; CD44  CD25 
[TN2]; CD44  CD25  [TN3]; CD44  CD25  [TN4]).
Comparison of the pro-thymocyte subsets in wild-type
and KitY719F/Y719F mice (Fig. 3 A) showed normal propor-
tions in young (unpublished data) as well as in older mice.
It was possible that elimination of IL-7R / c signaling in
pro T cells in KitY719F/Y719F mice would reveal a role for
Kit-mediated PI 3-kinase signaling in thymocyte devel-
opment as mice double null for Kit and  c have no pro-
thymocytes (22, 29). As expected, mice lacking only  c
(Kit /   c
 ) had the typical IL-7R / c partial block at
the TN2 and TN3 to TN4 transition with normal dou-
ble- and single-positive subsets (for review see reference
28). But analysis of thymocyte development in KitY719F/Y719F
 c /  double-mutant mice revealed a block at the TN3
to TN4 stage as known from IL-7/ c receptor mutants,
and no additional arrest due to the KitY719F mutation was
observed (Fig. 3 B). Thus, in thymocyte development di-
rect activation of PI 3-kinase by Kit is not required, al-
though in a fetal blood-derived pro T cell line the p85
subunit of PI 3-kinase was recruited to the activated Kit
receptor (unpublished data).
Whereas the overall cellularity of thymi in KitY567F/Y567F
and control mice was comparable, pro-thymocyte subsets
were affected differentially by the mutation (Table II and
Figure 2. Age-dependent block in pro B cell development in
KitY567F/Y567F, but not in KitY719F/KitY719F mice. (A) Expression of B220,
CD43, CD24, BP-1, and IgM in BM cells of 14-mo-old KitY567F/Y567F,
KitY719F/Y719F mutant mice, and respective littermate controls. Stages of B
cell development were resolved according to Hardy et al. (27). The
B220  CD43  cells were analyzed for IgM expression (a–d) and B220 
CD43  cells were analyzed for CD24 and BP-1 expression (e–h). (B) Expres-
sion of CD24 and Kit (a and b) or CD19 (c and d) was analyzed within
the B220  CD43  gate in 9-mo-old KitY567F/Y567F and control mice.
Table I. Total Number of B Cell Progenitors in the Bone Marrow of KitY567F/Y567F and Control Mice
Cells/femur
 107
B220 /CD43 
 106
Fraction A
 106
Fraction B
 106
Fraction C
 106
B220 /CD43 
 106
Fraction D
 106
Fraction E
 106
Fraction F
 106
Kit / 
(n   4) 2.91   0.19 1.15   0.16 0.44   0.08 0.48   0.24 0.27   0.03 5.8   0.93 2.82   0.61 0.89   0.06 1.92   0.46
KitY567F/Y567F
(n   5) 2.68   0.76 0.65   0.18 0.47   0.19 0.16   0.08 0.11   0.03 2.52   0.55 0.67   0.22 0.21   0.08 1.51   0.38
P   0.534 P   0.003 P   0.782 P   0.06 P   0.0002 P   0.005 P   0.002 P   0.001 P   0.210Kit Signaling in Pro T and Pro B Cells 872
Fig. 3 C). FACS analysis of lineage negative thymocytes
revealed a clear relative increase in the most immature
TN1 (CD44  CD25 ) subset and a corresponding de-
crease in the downstream CD25  (TN2 and TN3) subset
starting at  6 mo and peaking at  9 mo in KitY567F/Y567F
mice. At 9 mo the increase of the TN1 subset in KitY567F/Y567F
mice was threefold compared with Kit /  littermate
controls (Fig. 3 C). Whereas the TN1 subset of the lin-
eage negative thymocytes appeared to be increased in mu-
tant mice, when compared with the total thymocyte
number the TN1 subset in the mutant mice was un-
Figure 3. Age-dependent block in pro T cell development in
KitY567F/Y567F, but not in KitY719F/Y719F mice. (A) Expression of CD4 and
CD8 was analyzed in 9-mo-old KitY719F/Y719F and littermate controls
(top). Gated lineage negative thymocytes from the same animals were
analyzed for CD44 expression to resolve the TN subsets (bottom). (B) Ex-
pression of CD4 and CD8 in total thymocytes (top) and of CD44 and
CD25 in lineage-negative thymocytes (bottom) was analyzed in Kit / 
 c /  and KitY719F/Y719F  c /  mice. (C) CD4 and CD8 expression was
analyzed on KitY567F/Y567F total thymocytes and controls (top) and expression
of CD44 and CD25 was analyzed in lineage-negative thymocytes (bottom)
from 6- and 9-mo-old KitY567F/Y567F and control mice.
Table II. Total Number of T Cell Progenitors for Each Subset in the Thymus of KitY567F/Y567F and Control Mice
Total thymocytes
 107
Lineage negative
 106
TN1
 106
TN2
 106
TN3
 106
TN4
 106
Kit /  (n   5) 6.36   0.75 1.55   0.17 0.17   0.10 0.08   0.02 1.0   0.21 0.30   0.08
KitY567F/Y567F (n   6) 6.67   1.08 0.98   0.23 0.25   0.08 0.04   0.02 0.5   0.19 0.18   0.04
P   0.589 P   0.001 P   0.137 P   0.005 P   0.003 P   0.01
Figure 4. Age-dependent block in pro T development in C57Bl/6J
mice treated with imatinib. (A) Thymus cellularity in 3–6-mo-old
C57Bl/6J mice treated with imatinib 45 mg/kg twice daily for 3 or 7 d or
with placebo (PBS, 7 d). The cellularity dropped from 7.15   0.8   107
(placebo, n   4) to 2.72   0.7   107 (3 d treatment, n   6) and 0.46  
0.2   107 (7 d treatment, n   6). (B) CD4 and CD8 expression analyzed
on total thymocytes of 6-mo-old C57Bl/6J mice treated with imatinib for
3 or 7 d or with placebo (top). Gated lineage-negative thymocytes analyzed
for CD44 and CD25 expression (bottom). (C) CD4 and CD8 expression
analyzed on total thymocytes of 6- or 9-mo-old C57Bl/6J mice treated
with imatinib for 7 d or with placebo (9-mo-old mice).Agosti et al. 873
stages (double and single positive) did not seem to be
affected. In fact, the overall cellularity of thymi in
KitY567F/Y567F mice was normal as well as the fraction of
single positive and double positive thymocytes (Fig. 3 C).
Moreover, CD4  and CD8  lymphocytes in peripheral
changed, but the TN2, TN3, and TN4 subsets were re-
duced by 50% (Table II). Hence, KitY567F/Y567F but not
KitY719F/Y719F mice display an age-dependent effect on
thymocyte development. However, this developmental
retardation was incomplete and differentiation into later
Figure 5. Age-dependent block in pro B cell
development in C57Bl/6J mice treated with ima-
tinib. (A) B220  CD43  BM cells were analyzed
for IgM expression (a–d), and B220  CD43  cells
were analyzed for CD24 and BP-1 expression (e–h)
in 3- and 9-mo-old C57Bl/6J mice treated with
imatinib 45 mg/kg twice daily for 7 d. (B) Expression
of CD24 and Kit (a and b) or CD19 (c and d) was
analyzed within the B220  CD43  gate in 9-mo-
old imatinib-treated and placebo-treated mice.
Table III. Total Number of B Cell Progenitors for Each Subset in the Bone Marrow of Normal Mice Treated for 7 d with STI571
Cells/femur
 107
B220 /CD43 
 106
Fraction A
 106
Fraction B
 106
Fraction C
 106
B220 /CD43 
 106
Fraction D
 106
Fraction E
 106
Fraction F
 106
Placebo treated
(n   4) 3.05   0.5 0.99   0.18 0.44   0.15 0.3   0.15 0.24   0.07 4.86   1.58 2.2   0.96 0.69   0.21 1.82   0.7
STI571 treated
(n   5) 2.86   0.33 0.76   0.09 0.41   0.04 0.25   0.09 0.06   0.02 1.52   0.34 0.07   0.02 0.1   0.02 1.33   0.33
P   0.545 P   0.07 P   0.699 P   0.583 P   0.01 P   0.02 P   0.02 P   0.01 0.268Kit Signaling in Pro T and Pro B Cells 874
blood, spleen, and bone marrow were also present in nor-
mal percentages (unpublished data).
Taken together, these results revealed an age-dependent
requirement for Kit-mediated Src kinase family signaling
but not PI 3-kinase signaling in early B and T cell develop-
ment similar to that seen in KitW/W mice. Whereas the de-
velopmental arrest is more complete in KitW/W mice (9)
than in KitY567F/Y567F mice, remarkably, both mutants dis-
play an age-dependent block at the same stages in B and T
cell development.
Pharmacological Inhibition of Early B and T Lymphopoiesis
with the Kit Tyrosine Kinase Inhibitor Imatinib (Gleevec®).
Targeted drug therapy for the treatment of malignancies
has had a dramatic breakthrough and clinical success with
the tyrosine kinase inhibitor imatinib (Gleevec®; Novar-
tis), an inhibitor of the ABL, platelet-derived growth fac-
tor receptor (PDGFR), and Kit kinases. Gleevec® is suc-
cessfully used to treat patients with chronic myelogenous
leukemia as well as patients with gastrointestinal stromal
tumor. Because of its specific effect on Kit signaling we
wondered whether pharmacological inhibition of Kit sig-
naling by Gleevec® would block normal steady-state lym-
phocyte development in adult mice, and this was indeed
the case. In young adult mice (3–6 mo) imatinib induced
a dramatic decrease in thymus size and cellularity after 3 d
and more pronounced after 7 d of treatment with the
drug (Fig. 4 A). The CD4  CD8  subset was strongly re-
duced, and analysis of the TN subsets revealed a partial
block at the TN1 stage. The lineage negative CD44 
CD25  thymocytes were increased at the expense of the
CD44  CD25  and the CD44  CD25  subsets (Fig. 4
B). These effects were even more dramatic upon treat-
ment of older mice ( 9 mo). In these older mice the
double positive subset was reduced to  10% of the con-
trol (Fig. 4 C).
To investigate the effect of imatinib on B cell differenti-
ation we analyzed the bone marrow of mice after 7 d of
drug treatment. In young adult mice a reduction of the
B220  CD43  CD24  BP-1  (fraction C) and B220 
CD43  IgM  (fraction D) subsets was observed similar to
that seen in KitY567F/Y567F mice. Again, treatment of older
mice produced a stronger phenotype. In these mice frac-
tion C pro B cells were reduced fourfold compared with
placebo-treated mice (Fig. 5 A and Table III). Similarly to
what was observed in KitY567F/Y567F mice, the Kit  and
CD19  cells within the B220  CD43  CD24high subset
were severely depleted in imatinib treated mice (Fig. 5 B).
Taken together these results demonstrate that acute inhibi-
tion of Kit signaling by imatinib strongly affected mouse
lymphopoiesis mimicking the effects seen in mice carrying
germline Kit loss of function mutations, KitW/W and
KitY567F/Y567F.
Figure 6. Analysis of mast cell
characteristics in vivo and in
vitro. (A) Histological analysis of
peritoneal mast cells isolated
from KitY719F/Y719F, KitY567F/Y567F,
and control mice. (B) Proliferation
and cell survival characteristics of
KitY567F/Y567F and WT BMMC.
Proliferation: Cells were stimu-
lated with KitL (as indicated). Data
are expressed as means   standard
error of triplicate samples. Apop-
tosis: KitY567F/Y567F and WT
BMMC were incubated and in
serum-free medium containing
KitL as indicated for 50 h. Per-
centage of apoptosis was deter-
mined by annexin V staining and
FACS® analysis. Experiments
were done in triplicate. Similar
results were obtained in three
independent experiments.Agosti et al. 875
Peritoneal Connective Tissue Mast Cells But Not Skin Con-
nective Tissue Mast Cells Are Affected in Both KitY567F/Y567F
and KitY719F/Y719F Mice. KitL and Kit play a critical role in
mast cell development and maintenance in the adult ani-
mal (7, 8). Interestingly, both the KitY719F and the KitY567F
mutation do not affect mast cell numbers in the dorsal skin
but peritoneal mast cell numbers are severely diminished
in these mice (Table IV). Staining with berberine sulfate
and alcian/safranin of peritoneal mast cells indicates that
although the mutations affect mast cell numbers they do
not affect their development and differentiation. Thus,
fully differentiated mast cells were detected, albeit at much
reduced numbers, in both KitY567F/Y567F and KitY719F/Y719F
mice (Fig. 6 A).
In contrast to this mast cell deficiency in vivo in KitY567F/Y567F
mice, KitL-mediated proliferation of KitY567F/Y567F BMMC
was markedly enhanced, particularly at low doses of KitL
(Fig. 6 B). Most likely this results from the effects of the
mutation on the recruitment of the tyrosine phophatase
SHP2 and the adaptor protein APS, which are affected by
the Y567F mutation (15, 16). Survival was marginally en-
hanced in KitY567F/Y567F BMMC.
Differential Effects of the KitY567F and the KitY719F Mutations
in Spermatogenesis. KitY567F heterozygous and homozygous
mice were viable, healthy, and they were born at Mende-
lian frequencies. Our previous analysis of gametogenesis in
KitY719F/Y719F mice showed lack of an effect of the mutation
on the embryonic stages of gametogenesis (18). In contrast,
in males spermatogenesis was blocked during the premei-
otic spermatogonial stages and oogenesis in females was af-
fected to a lesser degree during the cuboidal stage of follicle
development (18). The KitY567F mutation did not affect fer-
tility of homozygous mutant males and females and histo-
logical analysis confirmed these findings (Fig. 7). In tubules
of adult male mutant testis all stages of spermatogonial mat-
uration and differentiation are seen, although focal areas
( 5%) contained empty tubules (Fig. 7).They were found
in young, adult, and old mice and the severity was not age
related. Therefore, whereas Kit-mediated PI 3-kinase sig-
naling is a critical step in spermatogenesis; in contrast the
KitY567F mutation does not affect this process.
Discussion
In an attempt to understand the biological roles of RTK-
mediated Src family kinase and PI 3-kinase signaling in vivo
we have characterized the phenotypes of mice expressing
mutant Kit receptors, which fail to activate PI 3-kinase or
Src family kinase signaling, KitY719F and KitY567F, obtained
by a knock-in strategy. Blockade of either of the two signal-
ing pathways produces phenotypes in distinct cell popula-
tions in early B and T cell development, in mast cells, and in
spermatogenesis. But in most other cell types, mutant phe-
notypes are minor. Similar mutational analysis of PDGF re-
ceptor   chain signaling in vivo in which the analogous PI
3-kinase and Src binding sites were mutated gave rather dif-
Table IV. Number of Mast Cells in the Skin and Peritoneum of 
KitY719F/Y719F and KitY567F/Y567F Mice
Genotype Age Skin mast cells
Peritoneal mast cells
(% of total peritoneal cells)
wk cells/cm
Kit /  18–24 150   9 ( n   3) 3.2   0.76 (n   3)
KitY567F/Y567F 18–24 153   30 (n   3) 0.07   0.056 (n   3)
Kit /  a 16–32 199   18 (n   3) 3.58   1.69  (n   6)
KitY719F/Y719F a 16–32 223   13 (n   3) 0.98   0.64  (n   5)
aValues taken from reference 18.
Figure 7. Histological analysis
of adult testis in KitY719F/Y719F and
KitY567F/Y567F mice. Paraffin
sections  obtained from Kit / ,
KitY719F/Y719F, and KitY567F/Y567F
mice stained with hematoxylin-
periodic acid-Schiff’s are shown.
Empty tubules in the KitY567F/Y567F
testis are indicated by arrows.Kit Signaling in Pro T and Pro B Cells 876
ferent results (30). On one hand the PI 3-kinase binding site
mutation produced severe phenotypes in many cell types. In
contrast, the Src binding site mutation had a limited pheno-
type in oligodendrocyte development. These results would
suggest that PDGF-mediated PI 3-kinase signaling is critical
for PDGF function in vivo. Therefore, analogous mutations
in the closely related Kit and PDGF receptor   chain have
very different in vivo consequences. This raises the possibil-
ity that the cellular context in which the receptor functions
may have a very critical role.
Whereas the Y719F mutation blocks the direct binding
by Kit of the p85 regulatory subunit of PI 3-kinase and its
activation, the Y567F mutation blocks Src kinase family
binding and activation as well as binding of the tyrosin
phosphatase SHP2 and APS family adaptor proteins (14–
16). Therefore, the interpretation of the consequences of
the Y567F mutation is quite complex as three different
signaling events have to be considered as well as the spe-
cific cellular context. The Src family of kinases includes
Src, Yes, Lyn, Fyn, Blk, Lck, and Fgr. Whereas, Src and
Yes are expressed ubiquitously, the other members are ex-
pressed in a tissue-specific manner and they may activate
distinct cellular responses (31, 32). Therefore, the Y567F
mutation may block activating as well as inhibitory signal-
ing events related to cell proliferation, cell survival as well
as receptor desensitization.
Both the KitY567F and the KitY719F mutation affect Kit
function only in specific developmental processes and this
is in contrast to other mutations in the Kit receptor gene
that broadly affect Kit function in hematopoiesis, gameto-
genesis, and melanogenesis. Thus, both mutations fail to af-
fect steady-state hematopoiesis and tissue mast cell num-
bers, but they substantially reduce peritoneal mast cell
numbers. Furthermore, although Kit has important func-
tions at multiple stages in embryonic and postnatal gameto-
genesis, the KitY719F mutation, and thus PI-3 kinase signal-
ing is critical only in a specific subset of the postnatal stages
in the ovary and testis, but the KitY567F mutation does not
affect these processes. The KitY719F but not the KitY567F mu-
tation affects activation of the PI 3-kinase Akt signaling cas-
cade known to have a critical role in mediating cell survival
(unpublished data), thus during the spermatogonial stages
Kit signaling appears to be critical in mediating cell survival
(18). We conclude, therefore, that in most cells that require
Kit, there are redundant signaling pathways, but that in
certain cell types, the PI-3 kinase pathway is critical.
In embryogenesis and in neonatal mice T cell develop-
ment is reduced, but permissive, and B cell development is
unaffected by loss of Kit function. In adult mice, recent
studies demonstrated a role for Kit function in both B and
T cell development (9). In viable Kit-null mutant mice an
age-dependent progressive decline of pro B and pro T cells
was observed with a concurrent loss of common lymphoid
progenitors in the bone marrow.
In B cell development, the Kit-null mutation, KitW,
does not affect the immunoglobulin repertoire and the es-
tablishment of the peripheral B cell compartment, but Kit
function is required for the maintenance of B lym-
phopoiesis from hematopoietic stem cells in adult mice
(9). In KitY567F/Y567F, but not in KitY719F/Y719F mice, we
demonstrate a partial block during the Kit-positive pro B
cell stages in agreement with these earlier results. Whereas,
hematopoietic stem cells and early progenitor numbers in
the BM determined by FACS® are normal in both
KitY567F/Y567F and in KitY719F/Y719F mice (unpublished data),
in BM of KitY567F/Y567F mice there was a progenitor deficit
with reduction in fraction C and D, but mature recirculat-
ing B lymphocytes were not significantly reduced. It is of
interest to note that this phenotype emerges late in life,
i.e., it is detectable at 9 mo and becomes more prominent
in older mice. Young adult animals (4-mo-old) are not af-
fected. It is possible that an age-related change in the bone
marrow microenvironment may contribute to the expres-
sion of this phenotype. Thus, signaling mediated by phos-
phorylation of KitY567 is important for Kit function in pro
B cell development in an age-dependent fashion. Identity
of the possible Src family kinase members involved in this
is not known. In addition, contributory roles of SHP-2
and the APS adaptor are difficult to evaluate as well. How-
ever, Kit-mediated activation of PI 3-kinase does not ap-
pear to be critical. In contrast to spermatogenesis in lym-
phocyte development a Kit-mediated survival signal is
either not critical or compensated for by another signaling
mechanism. The signal provided by Kit-PY567, which is
critical for lymphocyte development, on the other hand
may effect either cell proliferation and/or differentiation.
In T cell development loss of Kit function over time
produces a progressive loss of pro-thymocytes. There is an
age-dependent block at the TN2 stage and consequently
accumulation of CD44 CD25 Kit  TN1 cells as well as a
reduction of double-positive and single-positive thy-
mocytes (9). In thymi of KitY567F/Y567F, but not KitY719F/Y719F
mice, analysis of lineage-negative thymocytes showed an
increase of TN1 cells and a corresponding decrease of the
CD25  TN3 cell populations. But similar to thymi of mice
carrying the hypomorphic Kit allele KitWv, single- and
double-positive thymocyte numbers in KitY567F/Y567F thymi
were not affected. In T cell development age also plays an
important role. A mutant phenotype is first detected at
6 mo and is more severe at 9 mo. Thus, the effect of the
KitY567F mutation on thymocyte development is partial and
age related. In contrast the KitY719Fmutation does not affect
thymopoiesis.
Mast cells arise from progenitors in the bone marrow,
however, maturation and differentiation of these cells oc-
curs mainly in tissues where they reside (33, 34). Kit has a
major role in mast cell development and mast cell function
and mice with Kit loss of function mutations lack mast cells
in various tissues of the adult organism including skin, mu-
cosa of the GI tract, lung, peritoneal cavity, and its associ-
ated mesentery. Interestingly, in both KitY719F/Y719F and
KitY567F/Y567F mice mast cell numbers in dorsal skin sections
were not reduced. In contrast, both mutations affected
peritoneal mast cell numbers to differing degrees. Impor-
tantly, remaining peritoneal mast cells in the two mutant
mice were fully differentiated. Quite likely then the perito-Agosti et al. 877
neal microenvironment may not be able to compensate the
Kit signaling deficiencies.
The tyrosine kinase inhibitor STI571/imatinib is a spe-
cific inhibitor for the ABL, ARG, PDGFR, and Kit ki-
nases. It is used to treat chronic myelogenous leukemia and
gastrointestinal stromal tumor patients with considerable
success. An important clinical attribute of this drug is the
lack of major known side effects. Since imatinib also inhib-
its kinases other than Kit, notably ABL, blocking their
function may also contribute to the phenotypes in mice
treated with imatinib. A role for ABL in B cell develop-
ment has been inferred from phenotypes of mice with an
ABL-null mutation (35, 36). However, we consider this
possibility unlikely because (a) the phenotypes in pro B cell
development in ABL mutant mice are quite variable and
affect all pro B cell subsets, and (b), perhaps more impor-
tantly, treatment of mice with imatinib produces similar,
age-dependent pro T and pro B cell phenotypes as those
seen in mice carrying germline Kit mutations (this paper
and reference 9). The overlapping phenotypes caused by
genetic and pharmacological ablation suggest that both ge-
netic and pharmacological modes of Kit inhibition affected
the same signaling pathways in vivo. Moreover, similar to
mice carrying germline Kit mutations, which lack Kit func-
tion throughout live, our data using Imatinib show that
acute inhibition of Kit signaling in older mice rapidly
affects lymphopoiesis. The increased Kit dependency of
lymphopoiesis with age may result from age-dependent
changes in the bone marrow and the thymic microenviron-
ments such that Kit signaling becomes more critical. The
molecular nature of the age-associated changes remains to
be determined. The effect of STI571 on the immune sys-
tem’s response to an antigen has been assessed in a 4-week
study in rats (8-week-old). STI571 was administered orally
up to 60 mg/kg/d. Relative counts of lymphocyte subpop-
ulations in peripheral blood, thymus, spleen, and mesen-
teric lymph nodes revealed no obvious changes attributable
to either administration of STI571 or immunization of ani-
mals with KLH. There were no findings indicative of
an adverse immunotoxicological effect (Paul, G.R., U.
Junker, and P. Ulrich, personal communication).
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